Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akshay Sharma

Showing results (281-290 of 326) with videos related to

Pageof 33
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2024
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34<sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseVarun Katta, Kiera O'Keefe, Yichao Li, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Transplantation and Cellular Therapy|July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort StudyNeel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
Blood Advances|December 21, 2023
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipientsMatt S Zinter, Ruta Brazauskas, Joelle Strom, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Critical Illness Risk and Long-Term Outcomes Following Intensive Care in Pediatric Hematopoietic Cell Transplant RecipientsMatt S Zinter, Ruta Brazauskas, Joelle Strom, et al.
The New England Journal of Medicine|April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell DiseaseHaydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
The New England Journal of Medicine|April 3, 2026
Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell DiseaseAshish O Gupta, Akshay Sharma, Haydar Frangoul, et al.
Transplantation and Cellular Therapy|March 15, 2021
Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host DiseaseCaitlin W Elgarten, Yimei Li, Kelly D Getz, et al.
Transplantation and Cellular Therapy|March 29, 2023
Effect of Autograft CD34<sup>+</sup> Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System TumorsTristan E Knight, Kwang Woo Ahn, Kyle M Hebert, et al.
Bone Marrow Transplantation|September 4, 2023
No impact of CD34<sup>+</sup> cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastomaTristan E Knight, Kwang Woo Ahn, Kyle M Hebert, et al.
Pageof 33

Showing results (281-290 of 326) with videos related to

Sort By:
Pageof 33
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2024
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34<sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseVarun Katta, Kiera O'Keefe, Yichao Li, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Transplantation and Cellular Therapy|July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort StudyNeel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
Blood Advances|December 21, 2023
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipientsMatt S Zinter, Ruta Brazauskas, Joelle Strom, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Critical Illness Risk and Long-Term Outcomes Following Intensive Care in Pediatric Hematopoietic Cell Transplant RecipientsMatt S Zinter, Ruta Brazauskas, Joelle Strom, et al.
The New England Journal of Medicine|April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell DiseaseHaydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
The New England Journal of Medicine|April 3, 2026
Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell DiseaseAshish O Gupta, Akshay Sharma, Haydar Frangoul, et al.
Transplantation and Cellular Therapy|March 15, 2021
Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host DiseaseCaitlin W Elgarten, Yimei Li, Kelly D Getz, et al.
Transplantation and Cellular Therapy|March 29, 2023
Effect of Autograft CD34<sup>+</sup> Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System TumorsTristan E Knight, Kwang Woo Ahn, Kyle M Hebert, et al.
Bone Marrow Transplantation|September 4, 2023
No impact of CD34<sup>+</sup> cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastomaTristan E Knight, Kwang Woo Ahn, Kyle M Hebert, et al.
Pageof 33